Prognostic significance of muc4 expression in gallbladder carcinoma
World Journal of Surgical Oncology volume 10, Article number: 224 (2012)
Mucins are high molecular glycoproteins and play protective and lubricating roles in various epithelial tissues. Deregulated expression of mucins is involved in carcinogenesis and tumor invasion. MUC4 expression has been identified as a poor prognostic factor in pancreatobiliary carcinomas. To date, the relation between MUC4 expression and prognosis in gallbladder carcinoma remains to be determined. Authors examined MUC4 expression in gallbladder carcinoma and investigated its impact on prognosis.
The expression profiles of MUC4, MUC1, MUC2 mucins in gallbladder carcinoma tissues from 63 patients were investigated using immunohistochemical staining.
For gallbladder carcinoma, positive staining of MUC4, MUC1, and MUC2 was 55.6%, 81.0%, 28.6%, respectively. There was a significant correlation between the expression of MUC4 and the expression of MUC1 or MUC2 (p = 0.004, p = 0.009, respectively). Univariate analysis showed that MUC4 expression (p = 0.047), differentiation (p < 0.05), T-stage (p < 0.05) and lymph node metastasis (p < 0.001) were significantly associated with poor survival. Expression of MUC1 and MUC2 was not correlated to survival. The backward stepwise multivariate analysis showed that MUC4 expression (p = 0.039) and lymph node metastasis (p = 0.001) were significant independent risk factors. In combined assessment of MUC4 and MUC2 expression, MUC4 positive and MUC2 negative group showed a significantly worse outcome than MUC4 negative groups(MUC4-/MUC2+ and MUC4-/MUC2-) and MUC4/MUC2 co-expression group(MUC4+/MUC2+) (p < 0.05).
MUC4 expression in gallbladder carcinoma is an independent poor prognostic factor. Therefore, MUC4 expression may be a useful marker to predict the outcome of patients with surgically resected gallbladder carcinoma. MUC2 expression may have prognostic value when combined with MUC4 expression.
Gallbladder carcinoma still has a poor prognosis with 5-year overall survival rates at less than 15% [1, 2]. Complete surgical resection for gallbladder carcinoma is the only potentially curative treatment option, but even in patients treated by curative resection, many of them showed poor outcome due to the high recurrence rate . The commonly reported prognostic factors including pathologic stages are insufficient to predict either the clinical course or the biological behavior of gallbladder carcinoma. Therefore, investigation of new prognostic biomarkers is needed to predict the biological behavior of gallbladder carcinoma.
Mucins are high-molecular weight glycoproteins with oligosaccharides attached to serine or threonine residues of the mucin core protein backbone by O-glycosidic linkages. Mucins can be classified into two categories: transmembrane mucins (MUC1, MUC3, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17, MUC20 and MUC21) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6, MUC7, and MUC19) [4–6]. The mucins are produced by various epithelial cells and serve protective and lubricating roles. However, in damaged epithelia or tumor cells, there is a loss of polarity that occurs in association with the activation of a proliferation and survival program . Mucin gene expression is relatively organ-specific, and deregulated expression of one or more types of mucins occur with malignancy [8, 9].
In pancreatobiliary neoplasms, MUC1 expression is related to invasive proliferation of tumors and/or a poor outcome for patients, whereas the expression of MUC2 is associated with noninvasive proliferation of tumors and a favorable prognosis [10–12].
MUC4 is a large transmembrane mucin first found in the tracheobronchial mucosa . MUC4 is normally expressed in many epithelial tissues, including respiratory, colonic, and vaginal epithelia [14, 15] and is overexpressed in various carcinomas such as breast, lung, ovarian, pancreatic [16–19]. Recently, MUC4 expression was revealed to be a significant prognostic factor for bile duct carcinoma and pancreatic ductal carcinoma [19–21]. However, little information is known about the prognostic role of MUC4 in gallbladder carcinoma, although gallbladder carcinoma is the most common malignancy in the biliary tract. Therefore, authors investigated MUC4 expression in gallbladder carcinoma by immunohistochemical staining to determine whether MUC4 expression could be a potential prognostic factor for gallbladder carcinoma.
Surgically resected gallbladder carcinomas from 63 patients (17 male and 46 female patients) were studied retrospectively. The mean age of the patients was 66.9 years (range 36 to 88 years). The patients were diagnosed with gallbladder carcinoma and underwent operation between 1996 and 2006 in the Department of Surgery of Ewha Womans University Mokdong Hospital, South Korea. Resection with curative intent was performed in 53 patients (84%). Patients were selected for analysis based on the availability of paraffin-embedded tissue. Hematoxylin and eosin stained slides were reviewed for histological grade.
The pathological stage was classified according to the tumor node metastasis (TNM) classification of the American Joint Committee on Cancer Staging (AJCC) 6th edition . Clinicopathological data were reviewed and overall survival was analyzed. Follow-up was complete for 93% of enrolled patients. The follow-up period ranged from 1 to 122 months (mean, 36 months). This study was approved by the institutional review board of Ewha Womans University Mokdong Hospital.
The primary antibodies used in this study were MUC1 (mouse monoclonal Ab NCL-MUC-1, Novocastra laboratories, Newcastle, UK), MUC2 (mouse monoclonal Ab NCL-MUC-2, Novocastra laboratories), MUC4 (mouse polyclonal antihuman MUC-4, Zymed, SF, CA, USA).
The resected tumors of patients who received surgery were fixed in 10% buffered formalin and embedded in paraffin wax. Sections of 4 μm thickness were mounted on gelatin dichromate-coated glass slides, deparaffinized and rehydrated through graded ethanol solutions to distilled water. Antigen retrieval was performed by heating slides in a microwave oven in 10 mM citrate buffer (pH 6.0). Immunohistochemical staining was then done using a semiautomated machine (Bond™ Automated Immunohistochemistry, Leica, Wetzlar, Germany) and the bond polymer detection system with counterstain (Leica). The process included endogenous peroxidase blocking by 0.3% hydrogen peroxide for 5 minutes, incubation with primary antibodies for MUC1, MUC2 and MUC4 at room temperature for 30 minutes, polymeric HRP-linker antibody conjugates as the secondary antibody, and expression using 3, 3′-diaminobenzidine. The expression of MUC1, MUC2 and MUC4 showed brown-colored cytoplasmic and membranous staining. The results of immnuohistochemical staining were considered to be positive if more than 5% of the neoplastic cells were stained. The percentages of positively stained neoplastic cells were graded as follows: +, > 5% but < 20% of neoplastic cells stained; ++, > 20% but < 50% of neoplastic cells stained; and +++, > 50% of neoplastic cells stained. When 5% or fewer neoplastic cells were stained, the results were considered to be negative.
Statistical analysis was performed using the chi-square test, Fisher’s exact test, or the Spearman rank correlation test, where appropriate. Survival curves were plotted using the Kaplan-Meier method and differences between the survival curves were tested using the log-rank test. Multivariate survival analysis was performed using the Cox proportional hazards model. Backward stepwise multivariate analysis was also used to find independent prognostic factors. P-values less than 0.05 were considered statistically significant. All statistical analyses were conducted using SPSS 9.0 statistical software program (SPSS, Chicago, IL, USA).
MUC1, MUC2, and MUC4 expression profile in gallbladder carcinoma
Figure 1 shows the expression of the MUC4 (A), MUC1 (B), and MUC2 (C) in normal gallbladder tissue, while Figure 2 shows the expression of MUC4 (A), MUC1 (B), and MUC2 (C) in a patient with gallbladder carcinoma.
MUC 4 was expressed in 35 (55.6%) of the 63 gallbladder carcinomas. MUC1 was expressed in 51 (81.0%), and MUC2 was expressed in 18 (28.6%) carcinomas. There was significant correlation between the expression of MUC4 and the expression of MUC1 or MUC2 (P = 0.004, P = 0.009, respectively) (Table 1).
None of the expression of MUC1, MUC2, and MUC4 was significantly related to gender, age, differentiation, lymph node metastasis, or depth of invasion (Table 2).
Prognostic significance of MUC4, MUC1, and MUC2 expression in gallbladder carcinoma
Univariate analysis of factors related to overall survival in gallbladder carcinoma is summarized in Table 3. Patients with MUC4 expression had significantly worse survival than those without MUC4 expression (P = 0.048) (Figure 3). Other factors significantly correlated with survival were tumor differentiation, T stage, and lymph node metastasis. There was no significant difference in survival related to MUC1 expression. MUC2 expression was related to better survival but this was not statistically significant. The four factors (MUC4 expression, lymph node metastasis, T stage, and differentiation) selected from univariate analysis, based on a P-value < 0.05, were entered into the Cox proportional hazards model. This multivariate analysis showed that none of MUC4 expression (P = 0.079), lymph node metastasis (P = 0.080), T stage (P = 0.511), and differentiation (P = 0.291) were significant risk factors affecting the outcome (Table 4). In addition, backward stepwise multivariate analysis was used to find independent prognostic factors among these four factors listed in Table 4. Backward stepwise multivariate analysis showed that MUC4 expression (P = 0.039) and lymph node metastasis (P = 0.001) were statistically significant independent prognostic factors (Table 5).
In the combined assessment of MUC4 and MUC2 expression, the group with MUC4-positive and MUC2-negative pattern showed a worse outcome than the MUC4-negative groups (MUC4-/MUC2+ and MUC4-/MUC2-) and the MUC4/MUC2 co-expression group (MUC4+/MUC2+) (P < 0.05) (Figure 4).
Aberrant MUC4 expression has been observed in a variety of types of carcinoma. As to the biliary epithelial cells, MUC4 is not expressed in normal bile duct and gallbladder cells, but is expressed in cholangiocarcinoma cells [23, 24]. MUC 4 expression has been reported to be a significant independent factor for poor prognosis in several cancers such as bile duct carcinoma, invasive ductal carcinoma of the pancreas, and small sized lung adenocarcinoma [19–21, 25]. However, there has been no report on the prognostic role of MUC4 expression in gallbladder carcinoma. This study revealed for the first time that MUC4 expression in gallbladder carcinoma is an independent risk factor for poor outcome. This result suggests that MUC4 expression has an important role in predicting prognosis for patients with gallbladder carcinoma and has potential as a new molecular marker for clinical management of high risk patients. Given that this study shows the prognostic significance of MUC4 expression in gallbladder caricnoma, MUC4 expression should be considered a significant predictor for pancreato-biliary carcinomas including those of the gallbladder.
MUC4 seems to use multiple mechanisms to engage pathways leading to tumor cell progression
MUC4 has been shown to function in cell growth signaling through interaction with the ErbB2 family of growth factor receptors and activation of ErbB2 downstream signaling pathways, resulting in cell proliferation and survival [14, 26, 27]. A recent study by Miyahara et al. showed that MUC4 is upregulated and interacts with ErbB2 in gallbladder carcinoma . MUC4 can also promote tumor progression by repressing apoptosis by means of multiple mechanisms. The effects of MUC4 on conferring resistance to apoptosis have been found to be mediated by both ErbB2-dependent and ErbB2-independent mechanisms, indicating that tumor cells could exploit the versatile anti-apoptotic activities of MUC4 to acquire resistance to therapeutic agents, and augment cell survival . Repression of MUC4 expression might be a therapeutic target for eliminating some of those resistance mechanisms. However, the molecular mechanisms underlying MUC4 anti-apoptotic activity have not been well characterized and need to be investigated.
There have been small numbers of studies addressing the profile of MUC expression in gallbladder carcinoma. However, they have focused on MUC1 and MUC2 expression and their association with clinicopathological factors. MUC1 is a transmembrane glycoprotein, and is the most intensively studied member of the mucin family, making MUC1 overexpression one of the more common alterations in human cancers . Various studies showed that MUC1 expressed in tumors may function as an anti-adhesion molecule that inhibits cell-to-cell adhesion, permitting invasion into surrounding tissues [5, 30, 31]. MUC1 expression is significantly higher in gallbladder carcinoma than in normal and inflammatory gallbladder epithelium. Ghosh et al. and Yamato et al. reported MUC1 expression in 80% and 78.4% of gallbladder carcinoma, respectively, yet only traces in normal and inflammatory tissues [32, 33]. This study also observed high expression of MUC1 (81%) in gallbladder carcinoma. These observations support the theory that MUC1 expression could be particularly prevalent in gallbladder carcinoma, and could contribute to the progression of gallbladder carcinomas. Regarding the prognostic value of MUC1 expression in gallbladder carcinoma, several studies described an association with a poor outcome in univariate analysis [34, 35], but this study showed no relation between MUC1 expression and the outcome of patients with gallbladder carcinoma. This difference might be explained by various glycoforms of the MUC1 antigen, including underglycosylated, sialylated, and fully glycosylated forms , and these discrepancies in expression rates.
MUC2 is a gel-foaming secreted mucin that covers the intestinal mucosa, protecting the mucosal surface, and plays a role as lubricant. MUC2 has been found to be expressed mainly in the noninvasive tumors such as intraductal papillary mucinous neoplasm of the pancreas (IPMN) and mucin-producing bile duct tumor (MPBT) [10, 36], whereas MUC2 does not appear to be expressed in pancreatic ductal adenocarcinoma . High levels of MUC2 expression in indolent human pancreatobiliary neoplasms with a favorable prognosis may be related to the tumor suppressor activity of MUC2 .
The studies on MUC2 expression by gallbladder carcinoma showed that MUC2 expression is related to lower proliferative activity, contrary to MUC1 expression . These results suggest that MUC2 expression is related to noninvasive proliferation of the tumor, resulting in a favorable outcome. But MUC2 expression has not been related to clinical outcome in gallbladder carcinoma [34, 35]. This study also found that although MUC2 expression appeared linked to better survival, this was not statistically significant. These findings may be due to relatively low MUC2 expression in gallbladder carcinoma but further investigations are needed to clarify the mechanism of MUC2 expression.
This study found that MUC2 expression was correlated with MUC4 expression. When the combined status of MUC 4 and MUC2 expression was analyzed, MUC4-positive and MUC2-negative group was linked to a significantly worse outcome than in the MUC4-negative groups (MUC4-/MUC2+ and MUC4-/MUC2-) and the MUC4/MUC2 co-expression group (MUC4+/MUC2+). The point is that in MUC4-positive patients MUC2 expression status influences prognosis. These findings suggest that MUC2 expression may have prognostic value when combined with MUC4 expression.
This study shows that MUC4 expression is an independent poor prognostic factor in gallbladder carcinoma. Therefore, MUC4 expression may be a useful marker to predict the outcome of patients with surgically resected gallbladder carcinoma. MUC2 expression may have prognostic value when combined with MUC4 expression.
Manfredi S, Benhamiche AM, Isambert N, Prost P, Jouve JL, Faivre J: Trends in incidence and management of gallbladder carcinoma: a population-based study in France. Cancer. 2000, 89: 757-762. 10.1002/1097-0142(20000815)89:4<757::AID-CNCR6>3.0.CO;2-H.
Donohue JH: Present status of the diagnosis and treatment of gallbladder carcinoma. J Hepatobiliary Pancreat Surg. 2001, 8: 530-534. 10.1007/s005340100021.
Kim WS, Choi DW, You DD, Ho CY, Heo JS, Choi SH: Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma. J Gastrointest Surg. 2010, 14: 679-687. 10.1007/s11605-009-1140-z.
Rose MC, Voynow JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev. 2006, 86: 245-278. 10.1152/physrev.00010.2005.
Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004, 4: 45-60. 10.1038/nrc1251.
Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, Kitajima S, Goto M: Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int. 2011, 61: 697-716. 10.1111/j.1440-1827.2011.02734.x.
Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, Welsh MJ: Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature. 2003, 422: 322-326. 10.1038/nature01440.
Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL, Niehans GA: Mucin gene expression in normal, preneoplastic and neoplastic human gastric epithelium. Cancer Res. 1995, 55: 2681-2690.
Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS: Heterogenicity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993, 53: 641-651.
Higashi M, Yonezawa S, Ho JJ, Tanaka S, Irimura T, Kim YS, Sato E: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 1999, 30: 1347-1355. 10.1002/hep.510300609.
Yonezawa S, Nakamura A, Horinouchi M, Sato E: The expression of several types of mucin is related to the biological behavior of pancreatic neoplasms. J Hepatobiliary Pancreat Surg. 2002, 9: 328-341. 10.1007/s005340200037.
Tamada S, Goto M, Nomoto M, Nagata K, Shimizu T, Tanaka S, Sakoda K, Imai K, Yonezawa S: Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int. 2002, 52: 713-723. 10.1046/j.1440-1827.2002.01414.x.
Porchet N, Nguyen VC, Dufosse J, Audie JP, Guyonnet-Duperat V, Gross MS, Denis C, Degand P, Bernheim A, Aubert JP: Molecular cloning and chromosomal localization of a novel human tracheo-bronchial mucin cDNA containing tandemly repeated sequences of 48 base pairs. Biochem Biophys Res Commun. 1991, 175: 414-422. 10.1016/0006-291X(91)91580-6.
Bafna S, Kaur S, Batra SK: Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010, 29: 2893-2904. 10.1038/onc.2010.87.
Chaturvedi P, Singh AP, Batra SK: Structure, evolution, and biology of the MUC4 mucin. FASEB J. 2008, 22: 966-981.
Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, Batra SK: Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol. 2006, 19: 1386-1394. 10.1038/modpathol.3800646.
Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO: Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005, 18: 1295-1304. 10.1038/modpathol.3800445.
Hanaoka J, Kontani K, Sawai S, Ichinose M, Tezuka N, Inoue S, Fujino S, Ohkubo I: Analysis of MUC4 mucin expression in lung carcinoma cells and its immunogenicity. Cancer. 2001, 92: 2148-2157. 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO;2-6.
Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, Osako M, Takao S, Batra SK, Aikou T, Imai K, Yonezawa S: MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol. 2005, 58: 845-852. 10.1136/jcp.2004.023572.
Shibahara H, Tamada S, Higashi M, Goto M, Batra SK, Hollingsworth MA, Imai K, Yonezawa S: MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology. 2004, 39: 220-229. 10.1002/hep.20031.
Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S: MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res. 2006, 12: 4257-4264. 10.1158/1078-0432.CCR-05-2814.
Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M: American joint committee on cancer: cancer staging manual. 2002, Chicago: Springer, 6
Vandenhaute B, Buisine MP, Debailleul V, Clément B, Moniaux N, Dieu MC, Degand P, Porchet N, Aubert JP: Mucin gene expression in biliary epithelial cells. J Hepatol. 1997, 27: 1057-1066. 10.1016/S0168-8278(97)80150-X.
Matull WR, Andreola F, Loh A, Adiguzel Z, Deheragoda M, Qureshi U, Batra SK, Swallow DM, Pereira SP: MUC4 and MUC5AC are highly specific tumour-associated mucins in biliary tract cancer. Br J Cancer. 2008, 98: 1675-1681. 10.1038/sj.bjc.6604364.
Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, Batra SK, Imai K, Yonezawa S: MUC4 expression correlates with poor prognosis in small sized lung adenocarcinoma. Lung Cancer. 2007, 55: 195-203. 10.1016/j.lungcan.2006.10.013.
Carraway KL, Perez A, Idris N, Jepson S, Arango M, Komatsu M, Haq B, Price-Schiavi SA, Zhang J, Carraway CA: Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol. 2002, 71: 149-185.
Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA: Muc4/MUC4 functions and regulation in cancer. Future Oncol. 2009, 5: 1631-1640. 10.2217/fon.09.125.
Miyahara N, Shoda J, Ishige K, Kawamoto T, Ueda T, Taki R, Ohkohchi N, Hyodo I, Thomas MB, Krishnamurthy S, Carraway KL, Irimura T: MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer. 2008, 44: 1048-1056. 10.1016/j.ejca.2008.03.007.
Workman HC, Sweeney C, Carraway KL: The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res. 2009, 69: 2845-2852. 10.1158/0008-5472.CAN-08-2089.
Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 2009, 9: 874-885. 10.1038/nrc2761.
Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M: Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics. 2008, 8: 3329-3341. 10.1002/pmic.200800040.
Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, Krishnani N, Agrawal S, Ohkohchi N, Todoroki T: MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol. 2005, 31: 891-896. 10.1016/j.ejso.2005.03.008.
Yamato T, Sasaki M, Watanabe Y, Nakanuma Y: Expression of MUC1 and MUC2 mucin core proteins and their messenger RNA in gall bladder carcinoma: an immunohistochemical and in situ hybridization study. J Pathol. 1999, 188: 30-37. 10.1002/(SICI)1096-9896(199905)188:1<30::AID-PATH291>3.0.CO;2-Q.
Kashiwagi H, Kijima H, Dowaki S, Ohtani Y, Tobita K, Yamazaki H, Nakamura M, Ueyama Y, Tanaka M, Inokuchi S, Makuuchi H: MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. Oncol Rep. 2001, 8: 485-489.
Takagawa M, Muguruma N, Oguri K, Imoto Y, Okamoto K, Ii K, Ito S: Prediction of prognosis in gallbladder carcinoma by mucin and p53 immunohistochemistry. Dig Dis Sci. 2005, 50: 1410-1413. 10.1007/s10620-005-2854-8.
Osako M, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS, Sato E: Immunohistochemical study of mucin carbohydrates and core protein in human pancreatic tumors. Cancer. 1993, 71: 2191-2199. 10.1002/1097-0142(19930401)71:7<2191::AID-CNCR2820710705>3.0.CO;2-X.
Horinouchi M, Nagata K, Nakamura A, Goto M, Takao S, Sakamoto M, Fukushima N, Miwa A, Irimura T, Imai K, Sato E, Yonezawa : Expression of different glycoforms of membrane mucin(MUC1) and secretory mucin (MUC2, MUC5AC and MUC6) in pancreatic neoplasms. Acta Histochem Cytochem. 2003, 36: 443-453. 10.1267/ahc.36.443.
All authors declare no competing interests.
HKL conceived and designed the study; HKL, MSC and THK acquired the data; HKL and MSC analyzed and interpreted the data; HKL prepared for the manuscript. HKL and THK edited the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Lee, H.K., Cho, MS. & Kim, T.H. Prognostic significance of muc4 expression in gallbladder carcinoma. World J Surg Onc 10, 224 (2012). https://doi.org/10.1186/1477-7819-10-224
- Gallbladder carcinoma